N
AGIO icon

Natixis’s Agios Pharmaceuticals AGIO Stock Holding History

Natixis’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-465,000
Closed -$24M – 849
2021
Q1 		$24M Buy
465,000
+33,500
+8% +$1.66M 0.08% 230
2020
Q4 		$18.7M Buy
+431,500
New +$17.1M 0.07% 271
2020
Q1 		– Sell
-88,450
Closed -$4.24M – 688
2019
Q4 		$4.24M Buy
+88,450
New +$3.34M 0.03% 435
2015
Q3 		– Sell
-2,000
Closed -$222K – 307
2015
Q2 		$222K Buy
+2,000
New +$215K ﹤0.01% 330

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's AGIO Position: Q2 2021 in Review

Natixis sold out of Agios Pharmaceuticals (AGIO) in Q2 2021, closing a stake of 465,000 shares — an estimated $24M sold.

Natixis first reported a position in AGIO in Q2 2015 and held it in 4 quarters. The position peaked at $24M in Q1 2021. 185 funds tracked by Wall St. Rank hold AGIO as of Q2 2021.

  • Natixis reported no remaining Agios Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Natixis sold 465,000 Agios Pharmaceuticals shares in Q2 2021, an estimated $24M.
  • Natixis first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Natixis's Agios Pharmaceuticals position peaked at $24M in Q1 2021.
  • 185 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2021.

Based on Natixis's 13F filing for Q2 2021, filed 13 Aug 2021.